Additionally, these genes could be contributing to lung cancer risk directly through altered nitrosamine pharmacology—the CYP2A6 enzyme metabolically activates tobacco specific nitrosamines (TSNA) [2] and the nicotinic receptors are high-affinity binding sites for nitrosamines [3]. The gene discussed is CYP2A6; the disease is lung cancer.